CpG

ACTG CROI Presentation Demonstrates Superiority of HepB-CpG Vaccine Over Conventional Hepatitis B Vaccine Among People Living With HIV Who Have Not Previously Responded to Vaccination

Retrieved on: 
Wednesday, March 6, 2024

These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.

Key Points: 
  • These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.
  • People living with HIV, especially those with lower CD4 counts, often do not develop protective antibodies after receiving conventional hepatitis B vaccines.
  • The HepB-CpG (HEPLISAV-B®) vaccine includes a TLR-9 agonist adjuvant (CpG 1018® adjuvant) and is known to achieve high protection against hepatitis B among people living with HIV, but until now there have been limited data about its protection among people living with HIV who have not responded to conventional hepatitis B vaccines.
  • “Hepatitis B remains a significant issue for people living with HIV, as having both viruses increases the likelihood of liver complications,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

Synthetic DNA Sheds Light on Mysterious Difference Between Living Cells at Different Points in Evolution

Retrieved on: 
Wednesday, March 6, 2024

Is it just noise, a side effect of evolution, or does it have functions?

Key Points: 
  • Is it just noise, a side effect of evolution, or does it have functions?
  • A research team at NYU Langone Health sought to answer the question by creating a large, synthetic gene, with its DNA code in reverse order from its natural parent.
  • Then they put synthetic gene into yeast and mouse stem cells and watched transcription levels in each.
  • The study authors use yeast cells to assemble long DNA sequences in a single step, and then deliver the them into mouse embryonic stem cells.

Uvax Bio Receives Approval to Initiate a Phase 1 Clinical Trial of Novel HIV-1 Protein Nanoparticle Vaccine Candidates in Australia

Retrieved on: 
Tuesday, December 19, 2023

Uvax Bio, LLC , a privately held, clinical-stage vaccine company, today announced acknowledgement from Australian Therapeutic Goods Administration and approval from the Human Research Ethics Committee (HREC) to conduct a Phase 1 study of Uvax Bio's HIV-1 vaccine candidates in healthy volunteers in Australia.

Key Points: 
  • Uvax Bio, LLC , a privately held, clinical-stage vaccine company, today announced acknowledgement from Australian Therapeutic Goods Administration and approval from the Human Research Ethics Committee (HREC) to conduct a Phase 1 study of Uvax Bio's HIV-1 vaccine candidates in healthy volunteers in Australia.
  • Uvax Bio will work with their Australia-based clinical research partners Avance Clinical and the Nucleus Network study site to initiate this study in January 2024.
  • In a second preclinical immunogenicity study, immunization with Uvax Bio’s HIV-1 vaccine candidates elicited robust neutralizing antibody responses against the vaccine-matched virus in 99% of the animals.
  • “Our clinical team will immediately begin the preparation to initiate this trial in January 2024.”

Uvax Bio to give a Preclinical Development Update on its HIV-1 Vaccine at the World Vaccine Congress – West Coast 2023

Retrieved on: 
Tuesday, November 28, 2023

The presentation will be during the World Vaccine Congress – West Coast in Santa Clara, California on November 30th.

Key Points: 
  • The presentation will be during the World Vaccine Congress – West Coast in Santa Clara, California on November 30th.
  • Zhu added the innovative step to further modify his vaccine with a process called glycan trimming which demonstrated enhanced immune responses in the studies.
  • The 1c-SApNP platform technology and HIV-1 vaccine candidates have been exclusively licensed to Uvax Bio under a comprehensive agreement with Scripps Research.
  • “Our preclinical studies have confirmed both the safety and robust immunogenicity of our vaccine candidates for HIV-1.

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Retrieved on: 
Friday, November 3, 2023

The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death.

Key Points: 
  • The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death.
  • The data will be presented at the Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023) taking place at the San Diego Convention Center in San Diego, CA and virtually from November 1-5, 2023.
  • ELI-002 2P consists of 2 Amph-modified mKRAS peptide antigens, Amph-G12D and Amph-G12R (Amph-Peptides 2P), and an Amph-modified immune-stimulatory oligonucleotide adjuvant (Amph-CpG-7909).
  • 90% of immune responders had T cell responses to ≥ two mKRAS antigens, with 35% responding to all seven mKRAS antigens evaluated.

FOXO Technologies Launches Bioinformatics Services to Revolutionize Epigenetic Data Analysis

Retrieved on: 
Wednesday, July 19, 2023

FOXO Technologies Inc.™ (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today announced the launch of its cutting-edge Bioinformatics Services to accelerate breakthroughs in biology, biotechnology, and healthcare, and redefine the growing field of epigenetic research.

Key Points: 
  • FOXO Technologies Inc.™ (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today announced the launch of its cutting-edge Bioinformatics Services to accelerate breakthroughs in biology, biotechnology, and healthcare, and redefine the growing field of epigenetic research.
  • FOXO’s Bioinformatics Services offers a comprehensive platform of advanced data solutions tailored to meet the specific needs of clients in academia, healthcare, and pharmaceutical research.
  • “The launch of FOXO’s Bioinformatics Services marks a significant milestone for FOXO Technologies and the field of epigenetic research,” said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO.
  • However, harnessing the full potential of epigenetic data has long been hindered by the challenges of data processing, analysis, and interpretation.

BioVie Issues Letter to Shareholders

Retrieved on: 
Tuesday, July 18, 2023

Over 3,000 significant correlations were found linking reductions in DNA methylation of various CpGs and cognitive, biomarker and neuroimaging endpoints.

Key Points: 
  • Over 3,000 significant correlations were found linking reductions in DNA methylation of various CpGs and cognitive, biomarker and neuroimaging endpoints.
  • I have prepared this letter to shareholders to provide an update that synthesizes all the information that we have released and presented at recent medical conferences.
  • NE3107 reduced CSF phospho-tau levels by -1.66 pg/mL (p=0.0343) and the ratio of p-tau to amyloid beta 42 (Aβ42) by -0.0024 (p=0.0401).
  • P-tau and Aβ are traditional biomarkers of AD progression and have been the focus for AD researchers for decades.

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.

Retrieved on: 
Tuesday, April 4, 2023

BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model.

Key Points: 
  • BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model.
  • P18-BE3CRC is a drug candidate of PHAGERIA® platform technology, which is for the development and commercialization of bacteriophage-based drugs (Phageome API) effective for cancer control.
  • As comparing the cases with or without administering PHAGERIA® candidate, it was confirmed that administering PHAGERIA® candidate significantly inhibited tumorigenesis.
  • Mr. YOON, Kyung-won, CEO of iNtRON said that "We will accelerate follow-up research and development through partnerships with global companies.

Clover Announces Corporate Updates and Full Year 2022 Financial Results

Retrieved on: 
Wednesday, March 29, 2023

SHANGHAI, China, March 29, 2023 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced corporate updates and financial results for the year ended December 31, 2022.

Key Points: 
  • (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced corporate updates and financial results for the year ended December 31, 2022.
  • Comprehensive Global Vaccine Development: Clinical trial results released and published in 2022 consistently demonstrated that SCB-2019 elicited broad cross-neutralization across variants.
  • Notably, in January 2022, Clover published the final efficacy results from its global Phase 2/3 study of SCB-2019 in The Lancet.
  • Clover also announced positive data from its Phase 3 study evaluating SCB-2019 as a heterologous COVID-19 booster vaccine.

PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™

Retrieved on: 
Thursday, February 16, 2023

The preclinical research studied Infectimune™, PDS Biotech’s novel investigational infectious disease immune activating platform, and demonstrated the technology’s potency in eliciting CD4 T cells.

Key Points: 
  • The preclinical research studied Infectimune™, PDS Biotech’s novel investigational infectious disease immune activating platform, and demonstrated the technology’s potency in eliciting CD4 T cells.
  • The studies focused on comparing Infectimune™ induced immune responses following primary vaccination against influenza with immune responses induced by leading vaccine adjuvants.
  • This publication follows a recent article in Viruses highlighting the ability of Infectimune™ to generate a broad immune response against viruses, including SARS-CoV-2 and multiple strains of influenza.
  • Results from the study concluded that Infectimune™ dramatically enhanced CD4 T cell responses to recombinant HA-B proteins relative to AddaVax™ and AddaVax™ plus CpG.